TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.

计划入组 19 人 · 首次发布于 2025 年 6 月 6 日

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

计划入组 112 人 · 首次发布于 2019 年 1 月 29 日

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

计划入组 36 人 · 首次发布于 2016 年 7 月 12 日

Werner inhibitor (MSI-high cancers/sensitive cancers)

Kras Inhibitor (cancers)

Her2-DIDT

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Zymeworks

Canada

Arvinas

United States

Trastuzumab Deruxtecan Gains Regulatory Approvals in China and Europe for HER2-Positive Cancers

Two Novel Tumor-Agnostic Trials Target HER2-Positive Cancers and p53 Mutations at ESMO 2024

HUTCHMED Unveils First-in-Class HMPL-A251 Antibody-Targeted Therapy Conjugate with Superior Efficacy Against HER2-Positive Cancers